Skip to content

GlobalLawDBby GenieAI

Laws Search Sanctions Map Data Developers

Search the text of the law

Log in Get an API key

Laws Search Sanctions Map Data Developers

Log in Get an API key

The Global Law Database. Free to read, built for people and AI agents.

Explore

All laws
Search the text
Sanctions
Map of connections
Compare UK and EU

Developers

AI agents (MCP)
REST API
Bulk data
API keys

Coverage

United Kingdom
European Union
United States
Canada
Australia
France
Germany
Netherlands
Spain
Austria
Norway
Finland
Switzerland
Ireland

GlobalLawDB is made by GenieAI, London. It is not legal advice: check the official text before relying on it. Text comes from official publishers under their licences, listed on the Data page.

ThemeMatch my systemLightDark

European Union
Generics (UK) Ltd and Others v Competition and Markets Authority (C-307/18)
Consideration of the questions referre…
Questions 1 to 6 (Article 101 TFEU)
Questions 1 and 2 (potential competiti…
39

Generics (UK) Ltd and Others v Competition and Markets Authority (C-307/18)

Judgment of 30 Jan 2020law://eu/cjeu/2018/c-307-18/para_39@2026-11-11

39The assessment of whether there is potential competition must be carried out having regard to the structure of the market and the economic and legal context within which it operates.

Source: EUR-Lex, © European Union, 1998-2026. Reuse authorised under Decision 2011/833/EU.

Key facts

Court: Court of Justice · Fourth Chamber
Case: C-307/18 · ECLI:EU:C:2020:52
Decided: 30 Jan 2020
Procedure: Preliminary reference · referred by the Competition Appeal Tribunal (United Kingdom)
Applicants: Generics (UK) Ltd; GlaxoSmithKline plc and 4 more
Xellia Pharmaceuticals ApS; Alpharma LLC; Actavis UK Ltd; Merck KGaA
Defendant: Competition and Markets Authority
Rapporteur: D. Šváby
Advocate General: J. Kokott
Bench: 5 judges
M. Vilaras, S. Rodin, D. Šváby, K. Jürimäe, N. Piçarra
Language: English
Official: CURIA · EUR-Lex 62018CJ0307

Topics

Dominant position

History · 1 version

30 Jan 2020Reading

Connections

Interprets 1: Treaty on the Functioning of the European Union (consolidated 2016)2 provisions
Cited by 16: Booking.com BV and Booking.com (Deutschland) GmbH v 25hours Hotel Company Berlin GmbH and Others (C-264/23); Caronte & Tourist SpA v Autorità Garante della Concorrenza e del Mercato (C-511/23); Meliá Hotels International, S.A. v Associação Ius Omnibus (C-286/24); « Lukoil Bulgaria » EOOD v Komisia za zashtita na konkurentsiata (C-260/24); Teva Pharmaceutical Industries Ltd and Cephalon Inc. v European Commission (C-2/24 P)2 provisions; UBS Group AG, venant aux droits de Credit Suisse Group AG and Others v European Commission (T-84/22); UBS Group AG and Others v European Commission (T-441/21); ‘Tallinna Kaubamaja Grupp’ AS and ‘KIA Auto’ AS v Konkurences padome (C-606/23); Crédit agricole SA and Others v European Commission (T-386/21)2 provisions; Pharol, SGPS, SA v European Commission (T-181/22)2 provisions; Google LLC and Alphabet Inc. v European Commission (T-334/19); Qualcomm, Inc. v European Commission (T-671/19); Servier SAS and Others v European Commission (C-201/19 P)5 provisions; European Commission v Servier SAS and Others (C-176/19 P)3 provisions; European Commission v KRKA, tovarna zdravil, d.d (C-151/19); Lupin Ltd v European Commission (C-144/19)
Cites 23: Treaty on the Functioning of the European Union (consolidated 2016)3 provisions; Charter of Fundamental Rights of the European Union (consolidated 2016); Directive 2004/48/EC of the European Parliament and of the Council of of 29 April 2004 on the enforcement of intellectual property rights (Text with EEA relevance); Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use; Fernand Ullens de Schooten v État belge (C-268/15); Teresa Cicala v Regione Siciliana (C-482/10); Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance); Cristiano Marrosu and Gianluca Sardino v Azienda Ospedaliera Ospedale San Martino di Genova e Cliniche Universitarie Convenzionate (C-53/04); Intel Corp. v European Commission (C-413/14 P); Toshiba Corporation v European Commission (C-373/14 P); United Brands Company and United Brands Continentaal BV v Commission of the European Communities (27/76); NV Nederlandsche Banden Industrie Michelin v Commission of the European Communities (322/81); Konkurrensverket v TeliaSonera Sverige AB (C-52/09); Europemballage Corporation and Continental Can Company Inc. v Commission of the European Communities (6/72); Hoffmann-La Roche & Co. AG v Commission of the European Communities (85/76); Competition Authority v Beef Industry Development Society Ltd and Barry Brothers (Carrigmore) Meats Ltd (C-209/07); Stergios Delimitis v Henninger Bräu AG (C-234/89); Remia BV and others v Commission of the European Communities (42/84); F. Hoffmann-La Roche Ltd and Others v Autorità Garante della Concorrenza e del Mercato (C-179/16); Post Danmark A/S v Konkurrencerådet (C-209/10); Expedia Inc. v Autorité de la concurrence and Others (C-226/11); MasterCard Inc. and Others v European Commission (C-382/12 P); Massam Dzodzi v Belgian State (C-297/88, C-197/89)